Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 12: 1656 - 1665

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.12.002

Basic research

Correlation of WD 40 repeat 43 expression in lung adenocarcinoma and its effect on paclitaxel-resistance of cells

  • Xue ZHAO ,
  • Chunyan DONG
Expand
  • 1.Tongji University School of Medicine, Shanghai 200092, China
    2.Changshou Community Health Service Center of Putuo District, Shanghai 200060, China
    3.Department of Oncology, East Hospital, Tongji University, Shanghai 200120, China
DONG Chunyan, E-mail: cy_dong@tongji.edu.cn.

Received date: 2022-08-16

  Accepted date: 2022-12-11

  Online published: 2022-12-28

Supported by

National Natural Science Foundation of China(82073387)

Fold

Abstract

Objective ·To investigate the expression of WD 40 repeat protein 43 (WDR43) mRNA in lung adenocarcinoma (LUAD) cells and its correlation with the prognosis of LUAD patients, and analyze the effect of WDR43 on the paclitaxel-resistance of LUAD cells. Methods ·Cancer Therapeutics Response Portal (CTRP) was used to download the correlation coefficient between gene expression and paclitaxel sensitivity of LUAD cells, and the paclitaxel resistance-associated genes were screened. Gene Ontology (GO) function analysis and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis were used to analyze the paclitaxel resistance-associated genes, and WDR43 gene was chosen to perform further study. Human Protein Atlas (HPA) database was used to explore the expression and location of WDR43 protein in LUAD tissues. The cancer genome atlas (TCGA) database was retrieved to analyze the difference of WDR43 mRNA expression in LUAD tissues and normal lung tissues, the mutation of WDR43 in LUAD patients, and the correlation between WDR43 mRNA and clinicopathological factors. CaArray database was used to analyze the relationship between WDR43 mRNA and the prognosis of LUAD patients. Tumor Immune Estimation Resource (TIMER) was used to analyze the relationship between WDR43 expression and the infiltration level of immune cells in LUAD tissues. The expressions of WDR43 gene in LUAD cell lines were analyzed by Cancer Cell Line Encyclopedia (CCLE) database, the WDR43 differential-expressed LUAD cells were constructed and the effect of WDR43 expression on paclitaxel resistance was validated by MTT assay and plate colony formation assay. Results ·WDR43, a paclitaxel sensitivity-related gene, was selected by CTRP. The results of GO function analysis and KEGG pathway analysis showed that WDR43 and other genes were associated with rRNA processing and regulation of cell shape, and were enriched on the pathway such as herpes simplex virus 1 infection and cytosolic DNA-sensing pathway. The analysis results of HPA database showed that WDR43 protein was mainly expressed in the cellular nucleus, cellular cytoplasm and cellular membrane of LUAD tissues. The analysis results of TCGA database showed that the expression of WDR43 mRNA in LUAD tissues was higher than that in normal lung tissues (P=0.000), the expression in cancer tissues of LUAD smokers was higher than that of non-smokers (P=0.000), and the expression in TP53 mutant patients was also higher than that in TP53 wild-type patients (P=0.000). The analysis results of CaArray database showed that LUAD patients with WDR43 mRNA-high expression had poor prognosis (both P=0.000). The analysis results of TIMER database showed that the expression of WDR43 could promote the infiltration level of neutrophils, CD8+ T cells, myeloid-derived suppressor cells and macrophages, and inhibit the infiltration level of CD4+ T cells in LUAD tissues. In vitro experiments confirmed that overexpression of WDR43 could enhance the drug resistance of LUAD cells to paclitaxel. Conclusion ·The expression of WDR43 in LUAD tissues is significantly increased and negatively correlated with the prognosis of patients. Overexpression of WDR43 could enhance the paclitaxel resistance of LUAD cells.

Key words： WD40 repeat 43 (WDR43); lung adenocarcinoma; paclitaxel; chemoresistance; prognosis

Cite this article

Xue ZHAO , Chunyan DONG . Correlation of WD 40 repeat 43 expression in lung adenocarcinoma and its effect on paclitaxel-resistance of cells[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(12) : 1656 -1665 . DOI: 10.3969/j.issn.1674-8115.2022.12.002

References

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 O'KEEFFE L M, TAYLOR G, HUXLEY R R, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis[J]. BMJ Open, 2018, 8(10): e021611.
3 SHEN D J, WANG J F, WU J, et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage ⅡB-ⅢB resectable lung squamous cell carcinoma[J]. J Thorac Dis, 2021, 13(3): 1760-1768.
4 CHENG Z A, YU C T, CUI S H, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1[J]. Nat Commun, 2019, 10(1): 3200.
5 WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937.
6 MUELLER H S, FOWLER C E, DALIN S, et al. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel[J]. Proc Natl Acad Sci USA, 2021, 118(34): e2024055118.
7 CAI X Y, CHEN Z H, DENG M L, et al. Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma[J]. Ann Transl Med, 2020, 8(18): 1176.
8 SUGAWARA S, LEE J S, KANG J H, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer[J]. Ann Oncol, 2021, 32(9): 1137-1147.
9 SONDALLE S B, BASERGA S J, YELICK P C. The contributions of the ribosome biogenesis protein Utp5/WDR43 to craniofacial development[J]. J Dent Res, 2016, 95(11): 1214-1220.
10 PE?A C, HURT E, PANSE V G. Eukaryotic ribosome assembly, transport and quality control[J]. Nat Struct Mol Biol, 2017, 24(9): 689-699.
11 BI X J, XU Y H, LI T, et al. RNA targets ribogenesis factor WDR43 to chromatin for transcription and pluripotency control[J]. Mol Cell, 2019, 75(1): 102-116.e9.
12 PARANT J M, GEORGE S A, PRYOR R, et al. A rapid and efficient method of genotyping zebrafish mutants[J]. Dev Dyn, 2009, 238(12): 3168-3174.
13 COUCH F J, KUCHENBAECKER K B, MICHAILIDOU K, et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer[J]. Nat Commun, 2016, 7: 11375.
14 MENDOZA-FANDI?O G, LYRA P C M, NEPOMUCENO T C, et al. Two distinct mechanisms underlie estrogen-receptor-negative breast cancer susceptibility at the 2p23.2 locus[J]. Eur J Hum Genet, 2022, 30(4): 465-473.
15 LI Z J, FENG M, ZHANG J, et al. WD40 repeat 43 mediates cell survival, proliferation, migration and invasion via vimentin in colorectal cancer[J]. Cancer Cell Int, 2021, 21(1): 418.
16 HUANG Z Y, LI F, LI Q C. Expression profile of RNA binding protein in cervical cancer using bioinformatics approach[J]. Cancer Cell Int, 2021, 21(1): 647.
17 SCHAPIRA M, TYERS M, TORRENT M, et al. WD40 repeat domain proteins: a novel target class?[J]. Nat Rev Drug Discov, 2017, 16(11): 773-786.
18 UHLéN M, FAGERBERG L, HALLSTR?M B M, et al. Proteomics. Tissue-based map of the human proteome[J]. Science, 2015, 347(6220): 1260419.
19 SUN H J, SUN Q, QIU X, et al. WD repeat domain 43 promotes malignant progression of non-small cell lung cancer by regulating CDK2[J]. Int J Biochem Cell Biol, 2022, 151: 106293.
20 史清文. 天然药物化学史话: 紫杉醇[J]. 中草药, 2011, 42(10): 1878-1884.
20 SHI Q W. Historical story on natural medicinal chemistry of Taxol[J]. Chinese Traditional and Herbal Drugs, 2011, 42(10): 1878-1884.
Options
Outlines

/

〈 〉